51594
document
Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis . A double-blind , placebo-controlled study . Parenteral S-adenosylmethionine proved to be effective in reversing intrahepatic cholestasis in pregnant women . Based on these findings , a prospective multicenter , double-blind , placebo-controlled trial was planned to assess whether oral S-adenosylmethionine is effective in cholestatic patients with chronic liver disease . Accordingly , 220 inpatients ( 26 % chronic active hepatitis , 68 % cirrhosis , 6 % primary biliary cirrhosis ) with stable ( 1 month or more ) at least twofold increases in serum total and conjugated bilirubin and alkaline phosphatase volunteered for the trial . Serum markers of cholestasis significantly ( P less than 0.01 ) decreased after oral S-adenosylmethionine administration ( 1600 mg/day ) , and their values were significantly ( P less than 0.01 ) lower than the corresponding values in the placebo group . S-adenosylmethionine significantly ( P less than 0.01 ) improved subjective symptoms such as pruritus , fatigue , and feeling of being unwell , whereas placebo was ineffective . Two patients in the S-adenosylmethionine group and 9 controls ( P less than 0.05 ) withdrew from the trial for reduced compliance because of inefficacy of treatment . Oral S-adenosylmethionine was tolerated to the same extent as placebo . In conclusion , short-term administration of oral S-adenosylmethionine is more effective than placebo in improving clinical and laboratory measures of intrahepatic cholestasis and offers a new therapeutic modality for the symptomatic management of this syndrome .
51595
Intervention_Pharmacological
Oral S-adenosylmethionine
51596
Intervention_Control
placebo-controlled
51597
Intervention_Pharmacological
S-adenosylmethionine
51598
Intervention_Pharmacological
oral S-adenosylmethionine
51599
Intervention_Pharmacological
S-adenosylmethionine
51600
Intervention_Pharmacological
S-adenosylmethionine
51601
Intervention_Pharmacological
S-adenosylmethionine
51602
Intervention_Pharmacological
S-adenosylmethionine
51603
Intervention_Pharmacological
oral S-adenosylmethionine
51604
Intervention_Control
placebo
51605
Outcome_Physical
intrahepatic cholestasis
51606
Outcome_Physical
intrahepatic cholestasis
51607
Outcome_Physical
cholestatic patients
51608
Outcome_Physical
serum total
51609
Outcome_Physical
conjugated bilirubin and alkaline phosphatase
51610
Outcome_Physical
Serum markers of cholestasis
51611
Outcome_Physical
subjective symptoms such as pruritus , fatigue , and feeling of being unwell
51612
Outcome_Other
compliance
51613
Outcome_Other
inefficacy
51614
Outcome_Other
tolerated
51615
Outcome_Physical
clinical and laboratory measures of intrahepatic cholestasis
51616
Outcome_Other
symptomatic management
51617
Participant_Condition
intrahepatic cholestasis .